Overall rank by patents
#41,396
of 49,997 tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2021–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Lenz ranks #41,396 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.
USPTO PatentsView assignee plate
Corpus R41396 · US Corporation #41,396 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Lenz Therapeutics · this assignee
36 score
3D Lighting… · lowest
7 score
What this shows Lenz's Innovation Score is 36.5/100 (top 46% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Lenz Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2023. By volume, Lenz sits between Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut and Lewis Bolt & Nut Company.
Lenz Therapeutics, Inc. shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut
6 patents
Leishen Intelligent System Co., Ltd.
6 patents
Leman Micro Devices SA
6 patents
LenovoEMC Limited
6 patents
Lenze SE
6 patents
Leo Schachter Diamonds, L.L.C.
6 patents
Levicept Ltd
6 patents
Lewis Bolt & Nut Company
6 patents
Lenz Therapeutics, Inc.
6 patents
What this shows Lenz holds 6 patents at rank #41,432, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #41,432 in granted patent volume.
Other assignees with the most granted patents in Lenz's primary technology class.
Lenz's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
36 Top 46% higher than 54% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 2 | 33.3% |
| 2022 | 3 | 50.0% |
| 2023 | 1 | 16.7% |
Top 5 of 5 technology areas
Overall rank by patents
#41,396
of 49,997 tracked assignees
36.5 out of 100
What to do with this data
Lenz Therapeutics, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.